Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $6.43 USD
Change Today 0.00 / 0.00%
Volume 0.0
As of 8:10 PM 09/30/15 All times are local (Market data is delayed by at least 15 minutes).

elekta ab-b shs (EKTAF) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/1/14 - $10.75
52 Week Low
07/7/15 - $6.04
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ELEKTA AB-B SHS (EKTAF)

Related News

No related news articles were found.

elekta ab-b shs (EKTAF) Related Businessweek News

No Related Businessweek News Found

elekta ab-b shs (EKTAF) Details

Elekta AB (publ) develops and sells clinical solutions for the treatment of cancer and brain disorders worldwide. The company offers Leksell Gamma Knife, a system for cranial stereotactic radiosurgery; the Extend system for utilization of Leksell Gamma Knife Perfexion; and Leksell Stereotactic System for neurosurgery and biopsies. Its neuroscience solutions comprise Gamma Knife radiosurgery for the treatment of brain disorders; stereotactic neurosurgery; and surgical navigation accessories, as well as Elekta Neuromag TRIUX, a magnetoencephalography platform. The company also provides oncology treatment solutions, such as Precise Treatment System, a digital treatment system; Elekta Axesse, a stereotactic radiation therapy system; Elekta Compact, a gateway to RT for oncology centers; Elekta Synergy system that visualizes tumor targets and normal tissue, and their movement between and during fractions; treatment planning systems; oncology information systems solutions; Versa HD, a linear accelerator; and Elekta Infinity system for volumetric arc modulated therapy, as well as various treatment techniques. In addition, it offers brachytherapy solutions that include afterloading platforms; real-time prostate solutions; Oncentra Brachy, a radiotherapy treatment planning system; Esteya for treating skin cancer; and applicators. Further, the company provides software products, including MOSAIQ oncology information system; Oncology Informatics/Data Alliances that streamlines the flow of information in the cancer care team; medical oncology software; Clarity Soft Tissue Visualization, a software for radiation therapy; and METRIQ, a cancer registry data solution. It also offers installation and implementation, service and support, remote, upgrades and accessories, and financial solutions, as well as training, education, and consultative services. It primarily serves hospitals and academic institutions. The company was founded in 1972 and is headquartered in Stockholm, Sweden.

3,828 Employees
Last Reported Date: 09/1/15
Founded in 1972

elekta ab-b shs (EKTAF) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

elekta ab-b shs (EKTAF) Key Developments

Varian Medical Systems Files Civil Lawsuit against Elekta

Varian Medical Systems filed civil lawsuits and made a request that the United States International Trade Commission (USITC) initiate a patent infringement proceeding against Elekta on September 25, 2015. Elekta states that the claims have no merit and will defend itself vigorously. On June 16, 2015, William Beaumont Hospital and Elekta Ltd. filed a patent infringement suit against Varian Medical Systems Inc. in the United States District Court for the Eastern District of Michigan. The patents in suit are owned by William Beaumont Hospital and exclusively licensed to Elekta Ltd. The suit charges that Varian's True Beam linear accelerator infringes the patents.

Elekta AB to Showcase New Leksell Gamma Knife Icon at Congress of Neurological Surgeons Annual Meeting

Elekta's latest generation intracranial radiosurgery system, Leksell Gamma Knife® Icon™, will be in the spotlight (booth #336) at the 2015 meeting of the Congress of Neurological Surgeons (CNS), September 26-30 in New Orleans, Louisiana. Chosen by CNS to be highlighted as a key product in its Innovations Showcase, Icon features integrated stereotactic CT imaging, online Adaptive DoseControl™, ultra-precise dose delivery and the availability of frameless treatments. Icon is the only technology with Microradiosurgery™ capabilities allowing for the treatment of virtually any target the brain with ultra-high precision. Leksell Gamma Knife Icon received U.S. Food and Drug Administration 510(k) clearance in July, enabling U.S. health care providers to offer this advanced technology to their patients.

Elekta AB Announces Dividend, Payable on September 8, 2015

Elekta AB announced that a per-share dividend of SEK 0.50 to be distributed to shareholders. The record date for the dividend was set at September 3, 2015 and the payment is expected to be made on September 8, 2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
EKTAF:US $6.43 USD 0.00

EKTAF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Accuray Inc $5.29 USD +0.28
Eckert-Ziegler Bebig €0.96 EUR -0.02
Icad Inc $3.34 USD -0.03
MRI Interventions Inc $0.64 USD 0.00
RaySearch Laboratories AB kr113.25 SEK -3.00
View Industry Companies

Industry Analysis


Industry Average

Valuation EKTAF Industry Range
Price/Earnings 38.6x
Price/Sales 1.9x
Price/Book 3.2x
Price/Cash Flow 37.3x
TEV/Sales 1.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ELEKTA AB-B SHS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at